Q4 2024 Management View CEO Linda Marban highlighted the acceptance by the FDA of Capricor's Biologics License Application (BLA) for deramiocel, targeting treatment of Duchenne muscular dystrophy (DMD ...

Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne ...

Reports Q4 revenue $11.13M, consensus $9.87M. “2024 was a transformational year for Capricor and the patients we serve as we move closer to our ...

On a per-share basis, the San Diego-based company said it had a loss of 16 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research ...

Capricor Therapeutics (NASDAQ:CAPR) is scheduled to announce Q4 earnings results on Wednesday, March 19th, after market close. The consensus EPS Estimate is -$0.09 (-350.0% Y/Y) and the consensus ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have been given a consensus recommendation of “Buy” by ...

The biotechnology company posted adjusted earnings per share of -$0.16 for Q4, beating analyst estimates by $0.01. Revenue came in at $11.13 million, significantly above the consensus forecast of ...

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), on Monday, announced positive data from its ongoing HOPE-2 open-label extension trial, demonstrating the long-term efficacy of Deramiocel for the ...

Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference-- SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing ...

Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference-- SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing ...